187 related articles for article (PubMed ID: 23471305)
1. Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.
Orozco JJ; Bäck T; Kenoyer A; Balkin ER; Hamlin DK; Wilbur DS; Fisher DR; Frayo SL; Hylarides MD; Green DJ; Gopal AK; Press OW; Pagel JM
Blood; 2013 May; 121(18):3759-67. PubMed ID: 23471305
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.
Orozco JJ; Balkin ER; Gooley TA; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Hylarides MD; Shadman M; Green DJ; Gopal AK; Press OW; Pagel JM
PLoS One; 2014; 9(12):e113601. PubMed ID: 25460570
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.
Orozco JJ; Kenoyer A; Balkin ER; Gooley TA; Hamlin DK; Wilbur DS; Hylarides MD; Frost SH; Mawad R; O'Donnell P; Sandmaier BM; Fuchs EJ; Luznik L; Green DJ; Gopal AK; Press OW; Pagel JM
Blood; 2016 Jan; 127(3):352-9. PubMed ID: 26576864
[TBL] [Abstract][Full Text] [Related]
4. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
Nakamae H; Wilbur DS; Hamlin DK; Thakar MS; Santos EB; Fisher DR; Kenoyer AL; Pagel JM; Press OW; Storb R; Sandmaier BM
Cancer Res; 2009 Mar; 69(6):2408-15. PubMed ID: 19244101
[TBL] [Abstract][Full Text] [Related]
5. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
[TBL] [Abstract][Full Text] [Related]
6. Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.
Chen Y; Kornblit B; Hamlin DK; Sale GE; Santos EB; Wilbur DS; Storer BE; Storb R; Sandmaier BM
Blood; 2012 Feb; 119(5):1130-8. PubMed ID: 22134165
[TBL] [Abstract][Full Text] [Related]
7. Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and
Orozco JJ; Kenoyer AL; Lin Y; O'Steen S; Guel R; Nartea ME; Hernandez AH; Hylarides MD; Fisher DR; Balkin ER; Hamlin DK; Wilbur DS; Orcutt KD; Wittrup KD; Green DJ; Gopal AK; Till BG; Sandmaier B; Press OW; Pagel JM
Mol Cancer Ther; 2020 Dec; 19(12):2575-2584. PubMed ID: 33082277
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.
Pagel JM; Kenoyer AL; Bäck T; Hamlin DK; Wilbur DS; Fisher DR; Park SI; Frayo S; Axtman A; Orgun N; Orozco J; Shenoi J; Lin Y; Gopal AK; Green DJ; Appelbaum FR; Press OW
Blood; 2011 Jul; 118(3):703-11. PubMed ID: 21613259
[TBL] [Abstract][Full Text] [Related]
9. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
10. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.
Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Bush SA; Hui TE; Martin PJ; Mitchell D; Press OW
Blood; 1995 Feb; 85(4):1122-31. PubMed ID: 7849300
[TBL] [Abstract][Full Text] [Related]
11. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.
Pagel JM; Hedin N; Drouet L; Wood BL; Pantelias A; Lin Y; Hamlin DK; Wilbur DS; Gopal AK; Green D; Appelbaum FR; Press OW
Blood; 2008 Feb; 111(4):2261-8. PubMed ID: 18042793
[TBL] [Abstract][Full Text] [Related]
12. Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.
Wilbur DS; Thakar MS; Hamlin DK; Santos EB; Chyan MK; Nakamae H; Pagel JM; Press OW; Sandmaier BM
Bioconjug Chem; 2009 Oct; 20(10):1983-91. PubMed ID: 19731929
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
Buchmann I; Kull T; Glatting G; Bunjes D; Hale G; Kotzerke J; Rattat D; Dohner H; Reske SN
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):667-73. PubMed ID: 12599012
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome.
Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Hui TE; Martin PJ; Mitchell D; Press OW; Storb R; Bernstein ID
Blood; 1999 Aug; 94(4):1237-47. PubMed ID: 10438711
[TBL] [Abstract][Full Text] [Related]
15. Where do we stand with radioimmunotherapy for acute myeloid leukemia?
Walter RB
Expert Opin Biol Ther; 2022 May; 22(5):555-561. PubMed ID: 35350938
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive effects of (131)I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models.
Ruffner KL; Martin PJ; Hussell S; Nourigat C; Fisher DR; Bernstein ID; Matthews DC
Cancer Res; 2001 Jul; 61(13):5126-31. PubMed ID: 11431350
[TBL] [Abstract][Full Text] [Related]
17. α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation.
Frost SH; Miller BW; Bäck TA; Santos EB; Hamlin DK; Knoblaugh SE; Frayo SL; Kenoyer AL; Storb R; Press OW; Wilbur DS; Pagel JM; Sandmaier BM
J Nucl Med; 2015 Nov; 56(11):1766-73. PubMed ID: 26338894
[TBL] [Abstract][Full Text] [Related]
18. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
19. Development of [
Laszlo GS; Orozco JJ; Kehret AR; Lunn MC; Huo J; Hamlin DK; Scott Wilbur D; Dexter SL; Comstock ML; O'Steen S; Sandmaier BM; Green DJ; Walter RB
Leukemia; 2022 Jun; 36(6):1485-1491. PubMed ID: 35474099
[TBL] [Abstract][Full Text] [Related]
20. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.
Green DJ; Shadman M; Jones JC; Frayo SL; Kenoyer AL; Hylarides MD; Hamlin DK; Wilbur DS; Balkan ER; Lin Y; Miller BW; Frost SH; Gopal AK; Orozco JJ; Gooley TA; Laird KL; Till BG; Bäck T; Sandmaier BM; Pagel JM; Press OW
Blood; 2015 Mar; 125(13):2111-9. PubMed ID: 25628467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
